Dong-A Progresses In Diabetes With Lat Am Deal, New Study
This article was originally published in PharmAsia News
Executive Summary
With the global diabetes treatment market expected to show continued growth, South Korea's Dong-A ST is making progress in the sector by signing an additional licensing out contract for its new drug and successfully completing a Phase II U.S. study with a potential diabetic neuropathy therapy.